Hellenic Society for the Study of Bone Metabolism Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT02637180
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Hellenic Society for the Study of Bone Metabolism

Active Ingredients

Drugs in Phase 2 Trials (1)

denosumab (prolia) (2 trials)

Drugs in Other Trials (3)

alendronic acid (fosamax) (1 trial)

strontium ranelate (Protelos) (1 trial)

teriparatide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Histiocytosis (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4